Victory Capital Management Inc. Buys 38,672 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Victory Capital Management Inc. lifted its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 179.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 60,212 shares of the company's stock after purchasing an additional 38,672 shares during the period. Victory Capital Management Inc. owned 0.08% of Nurix Therapeutics worth $1,134,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. US Bancorp DE boosted its holdings in Nurix Therapeutics by 144.7% in the 4th quarter. US Bancorp DE now owns 1,424 shares of the company's stock worth $27,000 after buying an additional 842 shares during the period. Quarry LP boosted its holdings in Nurix Therapeutics by 3,746.2% in the 3rd quarter. Quarry LP now owns 2,500 shares of the company's stock worth $56,000 after buying an additional 2,435 shares during the period. Quest Partners LLC boosted its holdings in Nurix Therapeutics by 21.3% in the 3rd quarter. Quest Partners LLC now owns 7,458 shares of the company's stock worth $168,000 after buying an additional 1,312 shares during the period. Bellevue Group AG bought a new position in Nurix Therapeutics in the 3rd quarter worth approximately $180,000. Finally, EP Wealth Advisors LLC bought a new position in Nurix Therapeutics in the 3rd quarter worth approximately $240,000.

Insider Buying and Selling

In other Nurix Therapeutics news, CFO Houte Hans Van sold 5,825 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $14.49, for a total value of $84,404.25. Following the transaction, the chief financial officer now owns 33,724 shares in the company, valued at approximately $488,660.76. The trade was a 14.73 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gwenn Hansen sold 3,690 shares of the business's stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the transaction, the insider now owns 55,937 shares in the company, valued at $1,110,349.45. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 12,326 shares of company stock worth $213,449 in the last 90 days. 7.20% of the stock is owned by company insiders.

Remove Ads

Analyst Upgrades and Downgrades

Several research analysts recently commented on NRIX shares. BMO Capital Markets started coverage on shares of Nurix Therapeutics in a report on Friday, December 6th. They issued an "outperform" rating and a $35.00 price objective for the company. HC Wainwright raised their price target on shares of Nurix Therapeutics from $35.00 to $36.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. Leerink Partnrs raised shares of Nurix Therapeutics to a "hold" rating in a report on Monday, March 17th. Stifel Nicolaus raised their price target on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. Finally, Needham & Company LLC cut their price target on shares of Nurix Therapeutics from $29.00 to $28.00 and set a "buy" rating for the company in a report on Wednesday, January 29th. Three investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $30.88.

Nurix Therapeutics Stock Performance

NASDAQ:NRIX traded down $0.88 during trading hours on Friday, reaching $12.99. The company's stock had a trading volume of 2,288,289 shares, compared to its average volume of 870,393. The firm has a market capitalization of $985.77 million, a price-to-earnings ratio of -4.49 and a beta of 2.18. The firm has a 50-day simple moving average of $17.00 and a 200-day simple moving average of $20.77. Nurix Therapeutics, Inc. has a 1 year low of $11.90 and a 1 year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its earnings results on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. Equities analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.